Dated April 3, 2009
Exhibit 10.1
Dated
April 3, 2009
Between
Wafergen
Bio-Systems Inc
and
Prima
Mahawangsa Sdn Bhd
and
Expedient
Equity Ventures Sdn Bhd
and
Wafergen
Biosystems (M) Sdn Bhd
Proposed
subscription of shares in Wafergen Biosystems (M) Sdn Bhd (formerly known as
Global Dupleks Sdn Bhd)
Contents
This
Agreement is made on April 3, 2009 between:
(1)
|
Wafergen
Bio-Systems, Inc (WGBS.OB), a Nevada USA incorporated company with a
registered address and place of business at Bayside Technology Center,
00000 Xxxxxxx Xxxx, Xxxxxxx, XX 00000, XXX (“Existing
Shareholder”);
|
|
and
|
(2)
|
Prima
Mahawangsa Sdn Bhd (Company No. 833152-M), a company incorporated in
Malaysia with a registered address at 5th Floor, Bangunan XXXX, Xxxxx
Xxxxxxxx, Xxxxxxxxx Xxxxxxx , 00000 Xxxxx Xxxxxx (“PMSB”);
|
|
and
|
(3)
|
Expedient
Equity Ventures Sdn Bhd (Company No 780509-U), a company incorporated in
Malaysia with a registered address at Xxxxx 00, Xxxxxx Xxxx Pembangunan,
1016, Bandar Wawasan, Xxxxx Xxxxxx Xxxxxx, 00000, Xxxxx Xxxxxx (“EEV”);
|
|
and
|
(4)
|
Wafergen
Biosystems (M) Sdn Bhd (formerly known as Global Dupleks Sdn Bhd) (Company
No 795066-H), a company incorporated in Malaysia with a registered address
at Xxxx X-00-0, Xxxxx Xxxxxx 11, Xx 00, Xxxxx Xxx Xxxx Xxxx, 00000 Xxxxx
Xxxxxx (“Company”).
|
|
(PMSB
and EEV are collectively referred to as “Investors”)
|
Recitals
(A)
|
The
Company is a private company limited by shares incorporated under the laws
of Malaysia and has at the date of this Agreement an authorised share
capital of RM10,000,000 divided into 8,000,000 ordinary shares of RM1.00
each and 200,000,000 redeemable convertible preference shares of RM0.01
each.
|
(B)
|
The
Existing Shareholder is the legal and beneficial owner of the 300,000
ordinary shares of RM1.00 each in the Company, representing 100% of the
issued and paid-up ordinary share capital of the
Company.
|
(C)
|
The
Existing Shareholder, the Company and Malaysian Technology Development
Corporation Sdn Bhd (“MTDC”) have entered into
a Share Subscription and Shareholders’ Agreement dated 8 May 2008 (“SSSA”) where MTDC agreed
to subscribe for 888,888 Series A Redeemable Convertible Preference Shares
(“Series A RCPS”)
in the Company, pursuant to the terms and conditions in the
SSSA.
|
(D)
|
MTDC
is, as at the date of this Agreement, the legal and beneficial owner of
444,444 Series A RCPS in the Company, representing 100% of the issued and
paid up preference share capital of the
Company.
|
(E)
|
The
Existing Shareholder and the Company intend to raise a further
USD1,500,000 in multiple tranches, in addition to the USD2,000,000 to be
raised pursuant to the SSSA.
|
(F)
|
The
Existing Shareholder and the Company have requested the Investors to, and
the Investors have agreed to, participate in the Company by way of
subscription for
|
|
the
Series B RCPS (as defined below) upon the terms and subject to the
conditions set out in this
Agreement.
|
(G)
|
PMSB
and EEV have entered or will enter into a deed of adherence and have
agreed to accede to the relevant terms and conditions of the SSSA,
effective from the PMSB Initial Closing and EEV Initial Closing
respectively.
|
It
is agreed as follows:
1 Definitions
and Interpretations
1.1 Definitions
|
In
this Agreement, unless the context otherwise
requires:
|
Act
|
means
the Companies Xxx 0000;
|
Alpha
Stage
|
means
the successful completion of Alpha based on the written report from the
Principal Researcher from UPMC indicating that the SmartChip system has
performed to its specifications, that is the SmartChip system is able to
perform six SmartChip experiments by following instructions provided in
the SmartChip user manual using UPMC biological specimens and generate
gene expression data using fully integrated SmartChip components, such as
content ready chip, nano-dispenser and the real-time qPCR
instrument;
|
Articles
|
means
the articles of association of the Company;
|
Board
|
means
the board of directors of the Company;
|
PMSB
Initial Closing
|
means
completion of the subscription by PMSB of the relevant Tranche A Shares in
accordance with Clauses 3 and 4;
|
PMSB
Initial Closing Date
|
means
twenty one (21) days from the date of this Agreement or such later date as
PMSB, the Existing Shareholder and the Company may mutually agree
on;
|
PMSB
Subsequent Closing
|
means
upon fulfilment of the milestones provided for in Clause
3.1.1(b);
|
Conversion
Shares
|
means
the Shares resulting from the conversion of the RCPS, such Conversion
Shares to rank pari passu in all respects with all other then existing
Shares, and “Conversion Share” means one of the Conversion
Shares;
|
Deed
of Adherence
|
means
the Deed of Adherence dated the same day as this Agreement between the
Existing Shareholder, the Company, MTDC, PMSB and EEV;
|
Director
|
means
any director of the Company appointed on the Board including, where
applicable, any alternate director;
|
EEV
Initial Closing
|
means
completion of the subscription by EEV of the relevant Tranche A Shares in
accordance with Clauses 3 and 4;
|
EEV
Initial Closing Date
|
means
twenty one (21) days from the date of this Agreement or such later date as
EEV, the Existing Shareholder and the Company may mutually agree
on;
|
EEV
Subsequent Closing
|
means
upon fulfilment of the milestones provided for in Clause
3.1.2(b);
|
Encumbrance
|
means
any mortgage, charge, pledge, lien, assignment, hypothecation, security
interest, title retention, right of first refusal, pre-emption right,
option, preferential right or trust arrangement or other security
arrangement or agreement conferring a right to a priority of
payment;
|
Investors
|
means
PMSB and EEV;
|
IPO
|
means
the listing of the Company on any approved stock
exchange;
|
Parties
|
means
the Existing Shareholder, the Investors and the Company, and “Party”
refers to any one (1) of them;
|
RCPS
|
means
the Series A RCPS and/or the Series B RCPS;
|
Series
A RCPS
|
means
Series A Redeemable Convertible Preference Shares of the Company with
principal terms as set out in Schedule 1 of the SSSA including the
amendments as set out in the Deed of Adherence;
|
Series
B RCPS
|
means
Series B Redeemable Convertible Preference Shares of the Company with
principal terms as set out in Schedule 1 of this
Agreement;
|
Shares
|
means
ordinary shares of RM1.00 each in the share capital of the Company, and
“Share” refers to
any one (1) of them;
|
Subscription
Notice
|
means
the subscription notice to be issued by the New Investors to the Company
from time to time in accordance with this Agreement in the form as annexed
herewith in Schedule 3
|
Subscription
Price
|
means
the Ringgit Malaysia equivalent to USD2.25 calculated at the prevailing
exchange rate on the date payment of the Subscription Price is effected,
payable by the Investors for each Series B RCPS under this Agreement, out
of which RM0.01 is to be paid towards the par value of each Series B RCPS
and the difference between the Subscription Price and the par value of
RM0.01 (constituting the subscription premium) is to be credited to the
share premium account of the Company;
|
Tranche
A Shares
|
means
333,333 new Series B RCPS of RM0.01 each in the Company to be issued at
the Subscription Price;
|
Tranche
B Shares
|
means
333,333 new Series B RCPS of RM0.01 each in the Company to be issued at
the Subscription Price;
|
Warranties
|
means
the representations and warranties made by the Investor, the
Existing Shareholder and the Company, as set out in Schedule 2;
and
|
USD
|
means
United States Dollar, the lawful currency of the United States of
America;
|
1.2 Interpretation
|
In
this Agreement, unless the context otherwise
requires:
|
|
(a)
|
headings
and underlining are for convenience only and do not affect the
interpretation of this Agreement;
|
|
(b)
|
words
importing the singular include the plural and vice
versa;
|
|
(c)
|
words
importing a gender include any
gender;
|
|
(d)
|
an
expression importing a natural person includes any corporation or other
body corporate, partnership, association, governmental agency, two or more
persons having a joint or common interest, or any other legal or
commercial entity or undertaking;
|
|
(e)
|
a
reference to a party to a document includes that party's successors and
permitted assigns;
|
|
(f)
|
any
part of speech or grammatical form of a word or phrase defined in this
Agreement has a corresponding meaning;
and
|
|
(g)
|
a
warranty, representation, covenant or agreement on the part of two or more
persons binds them jointly and
severally.
|
2. Conditions
2.1 Conditions
Precedent
|
2.1.1
|
The
subscription for the Series B RCPS by PMSB is subject to, and conditional
upon, the fulfilment of the following conditions precedent within 21 days
from the date of this Agreement (subject to extension by agreement of
PMSB, the Existing Shareholder and the
Company):
|
|
(a)
|
the
approval and agreement of the investment committee of
PMSB;
|
|
(b)
|
the
successful completion of the due diligence exercise and PMSB being
satisfied with the results of their investigation or due diligence
exercise on the Company;
|
|
(c)
|
the
Company secretarial forms and documents (including the register of
members) having been updated and filed with the relevant authorities or
bodies to reflect the change in directorship, shareholder and shareholding
in the Company, in accordance with the terms and conditions of this
Agreement;
|
|
(d)
|
PMSB
being satisfied that all internal resolutions regarding the Company and
its activities are up to date and in order (where confirmation of
satisfaction shall not be unreasonably
withheld);
|
|
(e)
|
amendments
to the Articles as are necessary to reflect in full the terms of this
Agreement;
|
|
(f)
|
statutory
declaration signed by the Existing
Shareholder;
|
|
(g)
|
there
being no material adverse change in the financial condition or operations
of the Company or the Existing
Shareholder;
|
|
(h)
|
execution
of the deed of adherence referred to in Recital G;
and
|
|
(i)
|
the
Existing Shareholder entering into a product
licensing agreement with the Company in relation to the
SmartChipTM
Real-Time PCR System and SmartSlideTM
MicroIncubation System which provides that the intellectual property
rights to the improvements developed by the Company in relation to the
SmartChipTM
Real-Time PCR System and SmartSlideTM
MicroIncubation System shall vest in the Company and the Company shall
grant the Existing Shareholder a perpetual royalty free licence in
relation to the intellectual property rights to the improvements and a
right to sub-licence to any other party without territorial
restrictions.
|
|
2.1.2
|
The
subscription for the Series B RCPS by EEV is subject to, and conditional
upon, the fulfilment of the following conditions precedent within 21 days
from the date of this Agreement (subject to extension by agreement of EEV,
the Existing Shareholder and the
Company):
|
|
(a)
|
the
approval and agreement of the investment committee of
EEV;
|
|
(b)
|
the
successful completion of the due diligence exercise and EEV being
satisfied with the results of their investigation or due diligence
exercise on the Company;
|
|
(c)
|
the
Company secretarial forms and documents (including the register of
members) having been updated and filed with the relevant authorities or
bodies to reflect the change in directorship, shareholder and shareholding
in the Company, in accordance with the terms and conditions of this
Agreement;
|
|
(d)
|
EEV
being satisfied that all internal resolutions regarding the Company and
its activities are up to date and in order (where confirmation of
satisfaction shall not be unreasonably
withheld);
|
|
(e)
|
amendments
to the Articles as are necessary to reflect in full the terms of this
Agreement;
|
|
(f)
|
statutory
declaration signed by the Existing
Shareholder;
|
|
(g)
|
there
being no material adverse change in the financial condition or operations
of the Company or the Existing
Shareholder;
|
|
(h)
|
execution
of the deed of adherence referred to in Recital G;
and
|
|
(i)
|
the
Existing Shareholder entering into a product
licensing agreement with the Company in relation to the
SmartChipTM
Real-Time PCR System and SmartSlideTM
MicroIncubation System which provides that the intellectual property
rights to the improvements developed by the Company in relation to the
SmartChipTM
Real-Time PCR System and SmartSlideTM
MicroIncubation System shall vest in the Company and the Company shall
grant the Existing Shareholder a perpetual royalty free licence in
relation to the intellectual property rights to the improvements and a
right to sub-licence to any other party without territorial
restrictions.
|
2.2 Undertaking
by the Company
Subject
to the PMSB Initial Closing and EEV Initial Closing, the Company undertakes to
PMSB and EEV (as the case may be) to carry out the following within 1 year from
the PMSB Subsequent Closing and EEV Subsequent Closing (as the case may be)
(subject to extension by agreement with PMSB or EEV (as the case may
be)):
|
(a)
|
to
provide to PMSB and EEV (as the case may be) a clear arrangement on the
ownership of future intellectual property developed by the
Company;
|
|
(b)
|
to
put in place a comprehensive training programme to transfer the know-how
from US experts to the Malaysian team;
and
|
|
(c)
|
the
Company entering into a research and development agreement or
understanding to pursue agrobiotechnology research and development with a
reputable Malaysian entity.
|
2.3 Waiver
|
To
the extent permitted by law, PMSB and EEV may waive the fulfilment of any
condition precedent in Clause 2.1.1 or Clause 2.1.2 respectively, and any
undertaking in Clause 2.2.
|
2.4 Non-fulfillment
2.4.1
|
Unless
specifically waived under Clause 2.3, if the condition precedent in Sub
-clauses 2.1.1(a), (b) and (h) are not fulfilled within 21 days after the
date of this Agreement (or such later date as the relevant Parties may
mutually agree on):
|
|
(a)
|
this
Agreement shall automatically cease and terminate in relation to
PMSB;
|
|
(b)
|
all
obligations and liabilities of PMSB under this Agreement shall cease to
have effect;
|
|
(c)
|
PMSB
shall not have any claim against any other party in relation to this
Agreement; and
|
|
(d)
|
PMSB
shall pay the Existing Shareholder all costs and fees incurred by the
Existing Shareholder in relation to the preparation of this
Agreement,
|
but
notwithstanding anything to the contrary in this Clause, a party shall be liable
for any antecedent breach of this Agreement and continue to be liable in
relation to Clause 9.
2.4.2
|
Unless
specifically waived under Clause 2.3, if any condition precedent in
Sub-clauses 2.1.2 (a), (b) and (h) are not fulfilled within 21 days after
the date of this Agreement (or such later date as the relevant Parties may
mutually agree on):
|
|
(a)
|
this
Agreement shall automatically cease and terminate in relation to
EEV;
|
|
(b)
|
all
obligations and liabilities of EEV under this Agreement shall cease to
have effect; and
|
(c)
|
EEV
shall not have any claim against any other party in relation to this
Agreement; and
|
(d)
|
EEV
shall pay the Existing Shareholder all costs and fees incurred by the
Existing Shareholder in relation to the preparation of this
Agreement,
|
but
notwithstanding anything to the contrary in this Clause, a party shall be liable
for any antecedent breach of this Agreement and continue to be liable in
relation to Clause 9.
2.4.3
|
Unless
specifically waived under Clause 2.3, if the condition precedent in
Sub-clauses 2.1.1(c), (e), (f), (g) and (h) and Sub-clauses 2.1.2(c), (e),
(f), (g) and (h) are not fulfilled within 21 days after the date of this
Agreement (or such later date as the relevant Parties may mutually agree
on):
|
|
(a)
|
this
Agreement shall automatically cease and terminate in relation to PMSB and
EEV;
|
|
(b)
|
all
obligations and liabilities of PMSB and EEV under this Agreement shall
cease to have effect;
|
|
(c)
|
the
Existing Shareholder shall not have any claim against any other party in
relation to this Agreement; and
|
|
(d)
|
the
Existing Shareholder shall pay PMSB and EEV (as the case may be) all costs
and fees incurred by the PMSB and EEV (as the case may be) in relation to
the preparation of this Agreement,
|
but
notwithstanding anything to the contrary in this Clause, a party shall be liable
for any antecedent breach of this Agreement and continue to be liable in
relation to Clause 9.
3. Share
Capital
3.1 Subscription
for Preference Shares
|
3.1.1
|
Subject
to the terms and conditions of this Agreement, PMSB shall subscribe in
cash for 444,444 Series B RCPS, allocated across several
tranches as follows:
|
|
(a)
|
at
the PMSB Initial Closing Date, PMSB will subscribe for Tranche A Shares,
and the Company will allot and issue Tranche A Shares to PMSB, free from
any Encumbrance; and
|
|
(b)
|
upon
successful completion of the Alpha Stage (“PMSB Subsequent Closing”),
PMSB will subscribe for Tranche B Shares, and the Company will allot and
issue Tranche B Shares to PMSB, free from any
Encumbrance.
|
|
3.1.2
|
Subject
to the terms and conditions of this Agreement, EEV shall subscribe in for
222,222 Series B RCPS, allocated across several tranches as
follows:
|
|
(a)
|
at
the EEV Initial Closing Date, EEV will subscribe for Tranche A Shares, and
the Company will allot and issue Tranche A Shares to EEV, free from any
Encumbrance; and
|
|
(b)
|
upon
successful completion of the Alpha Stage (“EEV Subsequent Closing”),
EEV will subscribe for Tranche B Shares, and the Company will allot and
issue Tranche B Shares to EEV, free from any
Encumbrance.
|
|
3.1.3
|
The
Investors shall subscribe for the amount of shares and consideration as
follows:
|
Name
of Investor
|
Tranche
A
|
Tranche
B
|
Total
|
|||
No.
of RCPS
|
Consider-ation
(USD)
|
No.
of RCPS
|
Consider-ation
(USD)
|
No.
of RCPS
|
Consider-ation
(USD)
|
|
PMSB
|
222,222
|
500,000
|
222,222
|
500,000
|
444,444
|
1,000,000
|
EEVB
|
111,111
|
250,000
|
111,111
|
250,000
|
222,222
|
500,000
|
|
10
Share Subscription Agreement
|
The
principal terms of the Series B RCPS are set out in Schedule 1.
|
3.1.4
|
The
subscription for the Series B RCPS by PMSB is not dependant or
interconditional with the subscription of the Series B RCPS by EEV and the
subscription of the Series B RCPS by EEV is not dependant or
interconditional with the subscription of the Series B RCPS by PMSB, and
neither is dependant or interconditional on completion or performance of
the SSSA.
|
|
3.1.5
|
In
respect of each subscription for Series B RCPS under this Agreement, the
Company will issue a Subscription Notice to the Investors. The
Subscription Notice will specify the number of Series B RCPS to be
subscribed by the Investors under Tranche A at the PMSB Initial Closing
and EEV Initial Closing, and Tranche B at the PMSB Subsequent Closing and
EEV Subsequent Closing, and the Subscription
Price.
|
|
3.1.6
|
The
Existing Shareholder irrevocably confirms its waiver of all rights of
pre-emption whatsoever that it may have in connection with the issue and
conversion of the Series B RCPS to the Investors pursuant to the terms of
this Agreement.
|
4. Subscription
Completion Date
4.1
|
Subject
to fulfilment or waiver of all conditions precedent in Clause 2.1.1, the
completion of each allotment and issue of the Series B RCPS to PMSB
pursuant to this Agreement shall take place at the registered office of
the Company as follows:
|
(a) Tranche
A Shares at the PMSB Initial Closing Date; and
|
(b)
|
Tranche
B Shares at the PMSB Subsequent
Closing;
|
or such
other date and time as may be mutually agreed by the Company and PMSB in
writing.
4.2
|
Subject
to fulfilment or waiver of all conditions precedent in Clause 2.1.2, the
completion of each allotment and issue of the Series B RCPS to EEV
pursuant to this Agreement shall take place at the registered office of
the Company as follows:
|
(a) Tranche
A Shares at the EEV Initial Closing Date; and
(b) Tranche
B Shares at the EEV Subsequent Closing;
or such
other date and time as may be mutually agreed by the Company and EEV in
writing.
4.3
|
The
Investors shall cause or procure a cheque, bank draft or cashier’s order
in favour of the Company to be deposited, or a telegraphic or electronic
transfer made, to the bank account of the Company held with HSBC Bank
Berhad for the total subscription monies payable for the number of Series
B RCPS to be subscribed (as set out in the relevant Subscription Notice),
in exchange for the delivery by the Company of the
following:
|
|
11
Share Subscription Agreement
|
|
(a)
|
at
the PMSB Initial Closing and EEV Initial Closing, the share certificates
in respect of the Series B RCPS, a certified extract of the shareholders'
resolution of the Company approving the subscription of the Tranche A
Shares by PMSB at the PMSB Initial Closing and by EEV at the EEV Initial
Closing (as the case may be) (including amendment of the Articles of
Association of the Company where required), pursuant to the terms and
subject to the conditions of this
Agreement;
|
|
(b)
|
at
the PMSB Subsequent Closing and EEV Subsequent Closing, the share
certificates in respect of the Series B RCPS, a certified extract of the
shareholders' resolution of the Company approving the subscription of the
Tranche B Shares by at the PMSB Subsequent Closing and by EEV at the EEV
Subsequent Closing (as the case may be), pursuant to the terms and subject
to the conditions of this Agreement;
and
|
|
(c)
|
a
certified extract of the resolution of the Board confirming the allotment
and issue of the relevant number of the Series B RCPS to be subscribed by
the Investors:
|
|
(i)
|
at
both the PMSB Initial Closing and PMSB Subsequent Closing;
and
|
|
(ii)
|
at
both the EEV Initial Closing and the EEV Subsequent
Closing,
|
|
pursuant
to the relevant Subscription
Notice.
|
4A.
|
Utilisation
of Funds
|
The
Parties agree that 60% of the total investment raised through the issuance of
the Series A RCPS and the Series B RCPS will be utilised for the operations of
the Company in Malaysia. The remaining 40% of the total investment raised
through the issuance of the Series A RCPS and Series B RCPS shall be utilized in
the best interest of the Company.
5.
|
Undertakings,
Warranties and Representations by the
Parties
|
5.1
|
Subject
to any exceptions expressly and specifically disclosed in any
correspondence, communication, document or information in writing prior to
or after the execution of this Agreement and prior to the completion of
the subscription of the Series B RCPS, the Parties
warrant to each other that the information and statements set out
in the Warranties are true, accurate and correct in all respects at the
date of this Agreement. To this effect, the Warranties will be deemed to
be repeated during this period as if they had been entered into afresh
during the said period in relation to the facts and circumstances then
existing.
|
5.2
|
The
Parties acknowledge and agree that each of them entered into this
Agreement in reliance on the
Warranties.
|
5.3
|
Each
of the Warranties is separate and is to be construed independently of the
others and is not limited by reference to any of the other
Warranties.
|
|
12
Share Subscription Agreement
|
Save as
disclosed to the Investors in any correspondence, communication, document or
information in writing prior to or after the execution of this Agreement and
prior to the completion of this Agreement, no information relating to the Series
B RCPS or the Company will limit the nature of the Warranties given by the
Company under this Agreement, or will prejudice any claim to be made by the
Investors against the Company for any breach of the Warranties.
5.4
|
Each
Party will indemnify and will keep the other Parties indemnified against
all losses, damages, costs and expenses which the other Parties may incur
or be liable for in respect of any claim, demand, liability, action,
proceedings or suits arising out of or in connection with
:
|
|
(a)
|
a
breach of a Warranty;
|
|
(b)
|
any
Warranty not being true and correct in all respects;
or
|
|
(c)
|
any
Warranty being misleading in any
respect,
|
save and
except where any of the matters set out in Clauses 5.1 to 5.3 shall have been
apparent in any correspondence, communication, document or information in
writing and disclosed or provided to the Investors prior to or after the
execution of this Agreement and prior to the completion of this
Agreement.
6. Put
Options
6.1 Investor’s
Put Right for shares in the Existing Shareholder
The
Existing Shareholder will grant to each of the Investors an option to sell all
the Series B RCPS held by the Investors to the Existing Shareholder upon the
terms and conditions of the Put Agreement to be entered into between the
Existing Shareholder and the Investors.
6.2 Investor’s
Put Option for Series B RCPS or Conversion Shares
|
The
Investors shall each have the option to require the Existing Shareholder
to purchase all (but not less than all) of the Conversion Shares or Series
B RCPS held by the Investors, upon thirty (30) days’ notice in writing to
the Existing Shareholder. The price payable for each Conversion Share
shall be calculated based on the formula for the issue price per
Conversion Share set out in paragraph 5 of Schedule 1 of this Agreement
whereas the price payable for each Series B RCPS is USD2.25,
such price compounded at the rate of 8% per annum with yearly rests, up to
the date of exercise of the option, and at the discretion of the
Investors, may be satisfied by either cash or the issuance of shares in
the Existing Shareholder. The option shall be exercisable as
follows:
|
|
(a)
|
any
time after the PMSB Initial Closing or EEV Initial Closing (where
relevant) for as long as the PMSB or EEV (as the case may be) is the
holder of Series B RCPS in the Company, in
the event there is a material breach or default by the Company or the
Existing Shareholder in any of their representations, warranties,
undertakings, covenants and obligations
under
|
|
13
Share Subscription Agreement
|
|
this
Agreement which has not been remedied after 30 days written notice of such
material breach or default; or
|
|
(b)
|
any
time between 1 January 2011 and 31 December 2011 and subject to the
following:
|
|
(i)
|
the
share price of the Existing Shareholder’s shares is below USD2.25;
or
|
|
(ii)
|
due
to any breach or default attributable to the Existing Shareholder, the
Investor is unable to exercise its rights under the Put
Agreement.
|
7. Previous
Agreements and Prevalence of Agreement
7.1
|
This
Agreement and the documents referred to in its provisions are in
substitution for all previous agreements between all or any of the Parties
and contain the whole agreement between the Parties relating to the
subject matter of this Agreement.
|
8. Remedy
on an Event of Default
8.1
|
Each
of the following will be regarded as an Event of
Default:
|
|
(a)
|
either
of the Parties committing a breach of its obligations under this Agreement
and, in the case of a breach capable of remedy, failing to remedy the same
within twenty one (21) days of being specifically required in writing so
to do by the other Party; or
|
|
(b)
|
any
distress, execution, sequestration or other process being levied or
enforced upon or sued out against the property of any of the Parties which
is not discharged within ten (10) days;
or
|
|
(c)
|
any
encumbrancer taking possession of or a receiver or trustee being appointed
over the whole or any part of the undertaking, property or assets of any
of the Parties; or
|
|
(d)
|
the
making of an order or the passing of a resolution for the winding up of
any of the Parties, otherwise than for the purpose of a reconstruction or
amalgamation without insolvency or previously approved by the other
Parties (such approval not to be unreasonably
withheld).
|
8.2
|
In
the event of an Event of Default taking place prior to the PMSB Initial
Closing or EEV Initial Closing (as the case may
be),
|
|
(a)
|
where
the Company or the Existing Shareholder is the defaulting Party, PMSB and
EEV shall be entitled to terminate this
Agreement;
|
|
(b)
|
where
PMSB is the defaulting Party, the Company and the Existing Shareholder
shall be entitled to terminate this Agreement as against PMSB and to
proceed with the completion of this Agreement with
EEV;
|
|
(c)
|
where
EEV is the defaulting Party, the Company and the Existing Shareholder
shall be entitled to terminate this Agreement as against EEV and to
proceed with the completion of this Agreement with
PMSB;
|
|
14
Share Subscription Agreement
|
|
without
prejudice to any rights or remedies the non-defaulting Parties may have
against the defaulting Party for any antecedent
breach.
|
8.3
|
Notwithstanding
any provision in this Agreement to the contrary, this Agreement shall
remain in full force and effect for so long as shall be necessary to
fulfil and give effect to the arrangements and undertakings contained in
this Agreement.
|
8.4
|
Termination
of this Agreement for any cause in accordance with the provisions of this
Agreement shall not release any Party from any liability which at the time
of termination has already accrued to the other or which thereafter may
accrue in respect of any act or omission prior to such termination or
which has accrued in consequence of this
clause.
|
9. Confidentiality
Parties shall :
|
(a)
|
ensure
the confidentiality of this Agreement and the transactions contemplated in
this Agreement;
|
(b) not
disclose any provision of this Agreement except :
|
(i)
|
where
required by law or any relevant governmental regulatory body or competent
authority;
|
(ii) to any
financier or professional adviser acting for the party; or
|
(iii)
|
the
information is public knowledge otherwise than as a consequence of breach
of this Clause.
|
|
All
public announcements where references are made to the Investors or
companies related to the Investors shall only be made with the prior
written consent of the relevant Investor (which shall not be unreasonably
withheld), irrespective of the jurisdiction in which the announcement is
made.
|
|
This
restriction continues to apply after the expiration or sooner termination
of this Agreement without limit in point of time but ceases to apply to
information or knowledge which may properly come into the public domain
through no fault of the Party so
restricted.
|
10. Further
Assurance
Each
party shall execute and do all such documents and things as are necessary to
carry this Agreement into effect or to give full effect to this
Agreement.
11. Remedies
If a
Party does not comply with its obligations under this Agreement, the other
Parties are entitled to the remedy of specific performance and injunctive relief
(as may be applicable), and monetary compensation by itself is not an adequate
remedy.
|
15
Share Subscription Agreement
|
12. Waiver
and Variation
12.1 Rights
not affected
The
rights which each Party has under this Agreement shall not be prejudiced or
restricted by any delay in exercising or failure to exercise any right or remedy
under this Agreement. Unless otherwise agreed in writing, no waiver
by any party in respect of a breach shall operate as a waiver in respect of any
subsequent breach.
12.2 Cumulative
rights and remedies
The
rights and remedies provided in this Agreement are in addition to, and do not
exclude or limit, any rights or remedies provided by law or equity.
12.3 Variation
This
Agreement shall not be varied unless the variation is expressly agreed in
writing by each Party.
13. Severability
If any
provision of this Agreement is void or unenforceable, it shall be regarded as
deleted from this Agreement, and the remaining provisions shall continue to
apply.
14. Continuing
Effect
Notwithstanding
the completion of the transaction contemplated in this Agreement, the provisions
of this Agreement shall continue to survive or subsist so long as may be
necessary for the purpose of giving effect to each of them.
15. Time
Time
wherever mentioned in this Agreement shall be of the essence of this
Agreement.
16. Legal
Relationship
|
Nothing
in this Agreement shall create, or be regarded as creating, a partnership
or the relationship of employer and employee between the Parties. Neither
Party has any authority to bind the other in any
way.
|
|
The
Parties are all separate legal entities and as such no third parties shall
have any claim or recourse against the Company for the liabilities and
obligations of the Existing Shareholder to the abovementioned third
parties.
|
|
16
Share Subscription Agreement
|
17. Costs
and Expenses
The
Parties shall be liable for their own respective costs incurred, as
follows:
(a) due
diligence costs;
(b) fees
for the solicitors’, company secretary, tax advisers and accountants;
and
(c) notarisation
and the commercial register.
18. Assignment;
Successors
18.1 Assignment
Parties
may not assign or otherwise deal with its respective rights or benefits under
this Agreement without the prior written consent of the other
Parties.
18.2 Successors
and assigns
This
Agreement shall be binding upon the parties and their respective successors,
permitted assigns and personal representatives.
19. Notices
Without
affecting any other effective mode of service, any notice given under this
Agreement :
|
|
(a)
|
must
be in writing and may be delivered personally or sent by registered post
to the intended recipient at the address shown below or the address last
notified by the intended recipient to the sender
:
|
For the
Investors :
PMSB
5th
Floor, Bangunan XXXX,
Xxxxx
Xxxxxxxx, Xxxxxxxxx Xxxxxxx,
00000
Xxxxx Xxxxxx
Attn:
Darawati Hussain
Tel: x000
0000 0000
Fax: x000
0000 0000
or
x/x
Xxxxxxxxxxx
Xxx Xxx
X-0-0,
Xxxxx X,
00
Share Subscription Agreement
|
Plaza
Damas,
00 Xxxxx
Xxx Xxxxxxxx 0,
00000
Xxxxx Xxxxxx
Attn:
Norazharuddin Abu Talib
Tel: x000
0000 0000
Fax: x000
0000 0000
EEV
Suite
064, Kompleks Eureka,
University
Sains Xxxxxxxx,
Xxxxxx
00000,
Xxxxxx
Attn:
Xxxx Xxxxxx
Tel:
x000-0000000
Fax:
x000-0000000
For the
Existing Shareholder:
Wafergen
Bio-Systems Inc
Bayside
Technology Center,
00000
Xxxxxxx Xxxx,
Xxxxxxx,
XX 00000, XXX
Attn :
Xxxxxx Xxxxxx
Tel : x0
(000) 000-0000
Fax : x0
(000) 000-0000
For the
Company:
Wafergen
Biosystems (M) Sdn Bhd (formerly known as Global Dupleks Sdn
Bhd)
Suite
B.3(2), Ground Floor
KHTP
Business Centre
KHTP,
09000 Kulim
Kedah
Darul Aman, Malaysia
Tel :
x0000 000 0000
|
18
Share Subscription Agreement
|
Fax :
x000 000 0000
Attn:
Nazri Said
|
(b)
|
must
be signed; and
|
|
(c)
|
will
be taken to be duly given or made :
|
|
(i)
|
(in
the case of delivery in person) when delivered, received or left at the
above address; and
|
|
(ii)
|
(in
the case of delivery by registered post) 48 hours after posting, and in
proving service it shall only be necessary to prove that the communication
was contained in an envelop which was duly addressed and posted in
accordance with this Clause,
|
|
but
if delivery, receipt or service occurs, or will be taken to occur, on a
day on which business is not generally carried on in the place to which
the communication is sent or is later than 4 p.m. (local time) it will be
taken to have been duly given or made at the commencement of business on
the next day on which business is generally carried on in the
place.
|
20. Entire
agreement
This
Agreement is the entire agreement between the Parties in respect of its subject
matter and supersedes all previous agreements with respect to its subject
matter.
21. Counterparts
This
Agreement may be executed in any number of counterparts, and all counterparts
taken together constitute one and the same instrument.
22. Governing
Law and Jurisdiction
This
Agreement is governed by the laws of Malaysia, and each party submits to the
non-exclusive jurisdiction of the courts exercising jurisdiction in
Malaysia.
|
19
Share Subscription Agreement
|
SCHEDULE 1
Principal Terms of the Series B
RCPS
1. Subscription
Price and par value
The
subscription price for each Series B RCPS shall be Ringgit Malaysia equivalent
to USD2.25 calculated at the prevailing exchange rate on the on the date of
payment of the Subscription Price is effected. Each Series B RCPS
shall have a par value of RM0.01.
2. Premium
Each
Series B RCPS shall be issued at a premium being the difference between the
Subscription Price and the par value of RM0.01.
3. Dividend
Provision
There is
no specific dividend rate attached to the Series B RCPS and the Company is not
obliged to declare and pay any dividend while the Investors are holding the
Series B RCPS.
4. Liquidation
Preference
In the
event of any liquidation, dissolution or winding up of the Company, the holders
of the Series B RCPS will be entitled to receive only in preference to the
holders of Shares, and not the Series A RCPS (which rank pari passu for the
purposes of this provision), the relevant Subscription Price paid for the Series
B RCPS plus all accrued but unpaid dividends and dividends in arrears, if
any.
5. Conversion
Each
holder of the Series B RCPS will have the right, at the option of the holder at
any time, to convert all or part of the Series B RCPS into such number of Shares
as may be determined in accordance with the following formula:
A
x (Total
Number of + Total Number of
RCPS
|
(A + B + USD10 million) RCPS
subscribed
subscribed by all
other =
N
|
By the
holder
holders (past and present)
of RCPS)
|
A
|
represents
the aggregate original investment amount in USD (comprising the
subscription moneys paid to the Company for subscription for RCPS) of the
holder in the Company
|
|
B
|
represents
the aggregate original investment amount in USD (comprising the
subscription moneys paid to the Company for subscription for RCPS) of all
other holders (past and present) of RCPS in the
Company
|
|
20
Share Subscription Agreement
|
The
conversion is to be effected by and subject to the redemption of the Series B
RCPS from funds legally available for distribution at the redemption price of
USD2.25 per Series B RCPS and the issuance of such number of new Shares to the
holder with the issue price based on the following formula:
Issue
price per Share
= A
N
and
applying the redemption monies towards such issue price.
PROVIDED
THAT
(i)
|
where
N includes any fractions, N is to be rounded downwards to the nearest
whole number
|
(ii)
|
where
the number of new Shares to be issued includes any fractions, such number
of new Shares is to be rounded downwards to the nearest whole
number
|
(iii)
|
where
the issue price includes any fractions of sen, the issue price is to be
rounded downwards to the nearest
sen
|
For the
purposes of this provision:
(a)
|
the
amount in USD of the investment amount is based on the value in USD of the
subscription moneys as at the respective date(s) of the relevant
subscription(s).
|
(b)
|
for
the avoidance of doubt, where any RCPS has been held by more than one
holder, such RCPS and investment amount in relation to the RCPS, is to be
counted only once.
|
To effect
the above conversion, a conversion notice shall be sent by the holder(s) of the
Series B RCPS to the Company not less than thirty (30) days before the intended
date of conversion. Such notice shall be in writing and shall fix the
date and the time for the conversion.
The
Company may from time to time consult with, and make proposals to, the holder(s)
of Series B RCPS in relation to the exercise of the holder(s)’ entitlement to
convert the Series B RCPS.
Completion
of the conversion of the Series B RCPS into Conversion Shares shall be effected
at the registered office of the Company unless agreed otherwise by the holder(s)
of the Series B RCPS and the Company. On the date fixed for
conversion, the holder(s) of the Series B RCPS shall deliver to the Company the
share certificate(s) for the relevant Series B RCPS in exchange for share
certificates in relation to the relevant amount of Conversion Shares resulting
from the conversion of those
Series B RCPS. If any share certificate so delivered to the Company
relates to any Series B RCPS which are not to be converted on that day, a fresh
share certificate for those Series B RCPS shall be immediately issued by the
Company to such holder(s).
|
21
Share Subscription Agreement
|
6. [Deleted]
7. Redemption
Rights
|
The
holders of the Series B RCPS may at any time after 31 December 2011,
subject to the completion of the PMSB Subsequent Closing or EEV Subsequent
Closing (where relevant), by giving a thirty (30) day notice of redemption
in such form as may be acceptable to the Company (“Notice of Redemption”),
redeem any or all Series B RCPS registered in the name of the holder of
the Series B RCPS. The RCPS will be redeemable from funds legally
available for distribution at the redemption price (“Redemption Price”) which
comprises a par value of RM0.01 with redemption premium equivalent to the
difference between (i) the aggregate of the Subscription Price and such
price multiplied at the rate of 20% per annum prorated by day, up to the
date of the redemption based on a 365-days year (and without any
compounding or addition to the principal Subscription Price) and (ii) the
par value of RM0.01 per Series B RCPS plus all accrued but unpaid
dividends and dividends in arrears, if any.
|
All
redemption of the Series B RCPS shall be effected at the registered office of
the Company unless agreed otherwise by the holder(s) of the Series B RCPS and
the Company. On the date fixed for redemption, the holder(s) of the
Series B RCPS shall deliver to the Company the share certificate(s) for the
relevant Series B RCPS in exchange for payment in cash (by way of bank draft or
any other manner acceptable to the holder(s)) by the Company of the aggregate
Redemption Price for the time being payable for those Series B
RCPS. If any share certificate so delivered to the Company relates to
any Series B RCPS which are not to be redeemed on that day, a fresh share
certificate for those Series B RCPS shall be issued by the Company to such
holder(s).
No Series
B RCPS redeemed by the Company shall be capable of reissue.
8. Voting
Rights
The
holder of the RCPS will be entitled to the voting rights as referred to in
Section 148(2) of the Act.
9. Protective
Provisions
Without
the approval of the holders of at least a majority of the Series B RCPS, the
Company will not take any action, whether by merger, consolidation or otherwise,
that:
(a)
|
effects
a sale, lease, license or other disposition of all or substantially all of
the Company’s assets, property or business or undertakings in excess of
RM250,000.00;
|
|
22
Share Subscription Agreement
|
(b)
|
effects
or enters into any agreement regarding any transaction, or series of
transactions, which results in the holders of the Series B RCPS prior to
the transaction owning less than 50% of the voting power of the Company’s
Series B RCPS after the
transaction(s),
|
(c)
|
alters
or changes the rights, preferences or privileges of the Series B
RCPS,
|
(d)
|
increases
or decreases the number of authorized Series B
RCPS,
|
(e)
|
authorises
the issuance of securities having a preference over or on a parity with
the Series B RCPS,
|
(f)
|
changes
the number of directors,
|
(g)
|
amends,
modifies or repeals the Memorandum of Association and/or Articles of the
Company in a manner which adversely affects the holders of the Series B
RCPS,
|
(h)
|
effects
any recapitalization or reorganization, or any voluntary or involuntary
liquidation under applicable bankruptcy or reorganization legislation, or
any dissolution, liquidation, or winding up of the
Company,
|
(i)
|
declares
or pays dividends on or makes any distributions with respect to any share
capital of the Company.
|
For
purposes of these protective provisions, any reference to the Company will be
deemed to include any subsidiary of the Company.
10. No
Variation
The
rights attached to the Series B RCPS shall not be varied, modified or deleted
unless in accordance with paragraph 9 above.
[The remainder of this page is
intentionally left blank]
|
23
Share Subscription Agreement
|
SCHEDULE
2
Representations
and Warranties
1. Representations
and Warranties by the Investor
The
Investors warrant to the Company and the Existing Shareholder as
follows.
|
1.1
|
Capacity and
Authority
|
The
Investors are duly incorporated and validly exist under the laws of Malaysia and
have the power to own their assets and carry on their business as now being
conducted.
|
1.2
|
Power to execute this
Agreement
|
|
(a)
|
The
Investors have the right, power and authority, and have taken or will take
all action necessary, to validly execute, deliver and exercise their
rights, and perform their obligations under this
Agreement;
|
|
(b)
|
Other
than those set out in this Agreement, no other consent, approval,
authorization or other order of any court, regulatory body, administrative
agency or other order of any other governmental body is required for the
execution and delivery by the Investors of this Agreement or the
performance by the Investors of the transactions contemplated under this
Agreement;
|
|
(c)
|
This
Agreement is a valid and binding obligation of the Investors and is
enforceable against the Investors in accordance with its
terms;
|
|
(d)
|
The
execution, delivery and performance of this Agreement will not violate any
judgment, order or decree to which the Investors are subject and will not
be inconsistent with any constitutional documents or contracts to which
the Investors are a party to or otherwise binding on the Investors;
and
|
|
(e)
|
There
is no action, proceeding, claim or investigation pending against the
Investors before any court or administrative authority, which, if
determined against the Investors, may reasonably be expected to have a
material adverse effect on the Investors’ ability to perform the
obligations hereunder.
|
2.
|
Representations
and Warranties by the Existing Shareholder and the
Company
|
|
The
Existing Shareholder and the Company warrant to the Investors as
follows.
|
|
2.1
|
Capacity and
Authority
|
The
Company is duly incorporated and validly exists under the laws of Malaysia and
has the power to own its assets and carry on the Business.
|
2.2
|
Power to execute this
Agreement
|
|
24
Share Subscription Agreement
|
|
(a)
|
The
Existing Shareholder and Company have the right, power and authority, and
have taken or will take all action necessary, to validly execute, deliver
and exercise their rights, and perform their obligations under this
Agreement;
|
|
(b)
|
Other
than those set out in this Agreement, no other consent, approval,
authorization or other order of any court, regulatory body, administrative
agency or other order of any other governmental body is required for the
execution and delivery by the Existing Shareholder and the Company of this
Agreement or the performance by the Existing Shareholder and the Company
of the transactions contemplated under this
Agreement;
|
|
(c)
|
This
Agreement is a valid and binding obligation of the Existing Shareholder
and the Company and after fulfillment of the conditions precedent is
enforceable against the Existing Shareholder and the Company in accordance
with its terms;
|
|
(d)
|
The
execution, delivery and performance of this Agreement will not violate any
judgment, order or decree to which the Existing Shareholder and the
Company is subject and save as otherwise disclosed, will not be
inconsistent with any constitutional documents or contracts to which the
Existing Shareholder and/or the Company is a party to or otherwise binding
on the Existing Shareholder and/or the Company;
and
|
|
(e)
|
There
is no action, proceeding, claim or investigation pending against the
Existing Shareholder and/or the Company before any court or administrative
authority, which, if determined against the Existing Shareholder and/or
the Company, may reasonably be expected to have a material adverse effect
on the Existing Shareholder and the Company’s ability to perform the
obligations hereunder.
|
[The remainder of this page is
intentionally left blank]
|
25
Share Subscription Agreement
|
SCHEDULE
3
Subscription
Notice
From
: Wafergen
Biosystems (M) Sdn Bhd
To
: [Investor]
SHARE
SUBSCRIPTION AGREEMENT DATED ** (“Subscription Agreement”)
We refer to the Subscription Agreement
made between yourselves, [], the Existing Shareholder, and us. Terms defined in
the Subscription Agreement have the same meanings when used in this
notice.
We hereby give you notice, in
accordance with the terms and conditions of the Subscription Agreement, of your
required subscription for [222,222/111,111]* of the Series B RCPS at a total
Subscription Price of [USD500,000/USD250,000]* (equivalent to RM ** based on the
exchange rate as at **), such subscription to be completed on [date] at [time],
being the [PMSB/EEV] [Initial Closing/Subsequent Closing]*.
Dated
:
Yours
faithfully
For and
on behalf of
Wafergen
Biosystems (M) Sdn Bhd
By:
Name:
Title:
* (delete whichever is not
applicable)
|
26
Share Subscription Agreement
|
Execution
Executed
as an Agreement.
Signed
for and on behalf of WaferGen Bio-systems,
Inc (WGBS.OB) in the presence of:
|
||
Witness
|
Signatory
/s/
|
|
Name:
|
Name:
|
|
NRIC
No:
|
Designation:
|
|
NRIC
No:
|
Signed
for and on behalf of Prima Mahawangsa Sdn
Bhd (Company No833152-M) in the presence
of:
|
||
Witness
|
Signatory
/s/
|
|
Name:
|
Name:
|
|
NRIC
No:
|
Designation:
|
|
NRIC
No:
|
|
27
Share Subscription Agreement
|
Signed
for and on behalf of Expedient Equity Ventures Sdn
Bhd (Company No 780509-U) in the presence of:
|
||
Witness
|
Signatory
/s/
|
|
Name:
|
Name:
|
|
NRIC
No:
|
Designation:
|
|
NRIC
No:
|
Signed
for and on behalf of Wafergen Biosystems (M) Sdn Bhd
(Company No 795066-H) in the presence of:
|
||
Witness
|
Signatory
/s/
|
|
Name:
|
Name:
|
|
NRIC
No:
|
Designation:
|
|
NRIC
No:
|
28